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RESEARCH NOTE
Summary. Alterations in the erm(A) regulatory region of six clinical isolates of Staphylococcus epidermidis and one of
Staphylococcus haemolyticus displaying a constitutive resistance phenotype were investigated. A novel deletion of 10 bp with
respect to the corresponding sequence of Tn554 was identified in the attenuator of a constitutively expressed erm(A) gene of
one of the S. epidermidis isolates. Thus far, this is the smallest deletion conferring constitutive resistance in the translational
attenuator of erm(A) in a naturally occurring S. epidermidis strain of human origin. [Int Microbiol 2007; 10(2):147-150]
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Introduction
Resistance to macrolide, lincosamide, and streptogramin B
antibiotics (MLSB resistance) in staphylococci is mainly due
to the dimethylation of an adenine residue (A2058) located in
a highly conserved region of the 23S rRNA [6,24]. In staphy-
lococci, four major methylase gene classes, erm(A), erm(B),
erm(C), and erm(F), all of which play a role in MLSB resist-
ance [6,12,23], have been identified. Expression of the pre-
dominant erm genes in staphylococci, erm(A) and erm(C), is
either constitutive or inducible by 14- and 15-membered
macrolides. Resistance is not related to the class of the erm
determinant, but depends on the sequence of the regulatory
region upstream of the methylase gene and is explained by a
translation attenuation mechanism [6,13,24]. Constitutively
expressed erm(A) and erm(C) genes are of particular clinical
relevance since they also confer resistance to 16-membered
macrolides, lincosamides, streptogramin B antibiotics, and
the new ketolide drugs. However, in inducible MLSB resist-
ance, the strains are resistant to 14- and 15-membered
macrolides only, whereas 16-membered macrolides, lin-
cosamides, streptogramin B antibiotics, and ketolides remain
active [6,19]. The erm(A) gene, which is part of transposon
Tn554, is usually integrated at a specific site (att554) in the
Staphylococcus aureus chromosome. However, second inser-
tions have also been described in chromosomal and plasmid
sites, both in S. aureus and coagulase-negative staphylococci
(CoNS) [6,9,10,21,22,25]. Structural alterations in the
erm(A) regulatory region have been reported for constitutive
mutants derived from in-vitro selection experiments and for
constitutively expressed naturally occurring staphylococcal
plasmids [9,14,25].
In this work, we studied alterations in the regulatory region
of the constitutively expressed naturally occurring erm(A)
gene from six clinical isolates of Staphylococcus epidermidis
and one clinical isolate of Staphylococcus haemolyticus.
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Materials and methods
Bacterial strains and culture conditions. Six clinical strains of
S. epidermidis (0467, 4747, 6906, 6926, 7847 and 8377) and one of S. haemo-
lyticus (2505) were collected. All strains exhibited a constitutive resistance
phenotype and carried the erm(A) gene. The strains were isolated from the
respiratory tracts of patients in the Microbiology Service of the University
Clinical Hospital Lozano Blesa (Zaragoza, Spain) between October 2000
and November 2002. Initial identification was based on colony morphology,
microscopy appearance, and agglutination tests with the Pastorex Staph Plus
kit (Bio-Rad, La Coquette, France). Species were identified using the
WIDER Computerized System (Dade Behring, West Sacramento, CA,
USA). The isolates were cultured on Mueller-Hinton agar (MHA) (Bio-Rad,
La Coquette, France) at 37ºC and stored frozen (–80ºC) in sterile skimmed
milk.
Macrolide-lincosamide resistance testing. All strains had the
constitutive resistance phenotype, as confirmed by a triple-disk diffusion
technique carried out using a modification of the assay described by Seppälä
et al. [18]. The disks contained erythromycin (15 µg), azithromycin (15 µg),
clindamycin (2 µg) (Bio-Rad, La Coquette, France), and miocamycin (50 µg,
Neo-Sensitabs, Taastrup, Denmark).
PCR amplification. The presence of the erm(A), erm(B), and erm(C)
genes was tested by PCR, as reported by Sutcliffe et al. [20]. To detect struc-
tural alterations in the erm(A) and/or erm(C) regulatory regions, the PCR
assays described by Werckenthin and Schwarz [25] and by Lodder et al. [8]
were used. The expected PCR products were 592 bp for the erm(A) regula-
tory region and 295 bp for that of erm(C). All PCR amplifications were car-
ried out in a Perkin-Elmer Cetus DNA Thermal Cycler (Perkin-Elmer,
Norwalk, CT, USA), and the products were analyzed by electrophoresis
through 1.5% agarose gels. PCR reagents were purchased from Promega
(Madison, WI, USA). Three of the PCR amplicons of the erm(A) regulatory
region were purified (GFX PCR DNA and Gel Band Purification Kit,
Amersham Biosciences, Freiburg, Germany) and then sequenced
(DYEnamic ET Dye Terminator Cycle Sequencing Kit for MegaBACE
DNA Analysis Systems, Amersham). The software BLAST was used to
compare the sequences of the PCR products to that of the inducible erm(A)
gene of Tn554, available at the website of the National Center for
Biotechnology Information [http://www.ncbi.nlm.nih.gov]. A clinical con-
trol strain with an inducible phenotype, S. aureus 4850, which harbored
erm(A) and erm(C) with a complete attenuator, was used. The erm(A) regu-
latory region of the control strain was identical to that of Tn554 (database
accession no. X03216), whereas its erm(C) regulatory region was identical
to that of plasmid pE5 carrying erm(C) (database accession no. M17990).
Nucleotide sequence accession number. The nucleotide
sequence of the erm(A) regulatory region and partial erm(A) gene of strain
S. epidermidis 6926 was submitted to the GenBank database and assigned
accession no. DQ112022.
Results and Discussion
Analysis of the presence of the macrolide resistance genes
erm(A), erm(B), and erm(C) showed that four S. epidermidis
(strains 0467, 4747, 6926, and 7847) and one S. haemolyticus
(strain 2505) harbored both erm(A) and erm(C), whereas the
two remaining S. epidermidis isolates (6906 and 8377) car-
ried erm(A), erm(B), and erm(C). Sequence analysis of the
PCR fragment obtained from S. epidermidis 6926 identified a
novel 10-bp deletion in the erm(A) regulatory region. In S. epi-
dermidis 8377, a 121-bp deletion was observed in that region.
The remaining strains (S. epidermidis 0467, 4747, 6906, 7847,
and S. haemolyticus 2505) contained neither deletions nor tan-
dem duplications [14] in the regulatory region. erm(A) PCR
amplicons of strains S. epidermidis 6926, S. epidermidis 8377,
and S. epidermidis 6906 were sequenced.
The 10-bp deletion of S. epidermidis 6926 comprised
nucleotides 5358–5367 (AGTTCGTTAT), which corre-
sponded to part of the IR3 sequence located in the open read-
ing frame (ORF) of the 19-amino acid (aa) peptide (Fig. 1,
database accession no. DQ112022). Since truncated IR3 is
not able to form a stable mRNA secondary structure with
IR4, the latter will pair with IR5 and thereby render IR6 per-
manently accessible to ribosomes, allowing constitutive
erm(A) gene expression to occur. In addition, this strain also
harbored an erm(C) gene, but sequence analysis of the PCR
amplicon corresponding to the gene’s regulatory region
showed that it shared 100% identity with the regulatory
region of the S. aureus plasmid pE5, which carries erm(C)
and confers inducible MLSB resistance [11] (data not shown).
To our knowledge, this is the first report of a 10-bp deletion
in the regulatory region of an erm(A) gene in a S. epidermidis
clinical strain with a constitutive resistance phenotype.
Schmitz et al. [17] detected a 14-bp deletion that comprised
part of the ORF of the 19-aa peptide and part of IR3
(nucleotides 5344–5357). The deletion confers constitutive
resistance in S. aureus mutants—previously carrying an
inducible erm(A) gene—selected in vitro in the presence of
non-inducer antibiotics. Our work continues and extends this
study as it describes a smaller deletion in this region from a
naturally occurring S. epidermidis strain of human origin,
which suggests selective pressure in nature due to the wide-
spread use of MLSB antibiotics.
The 121-bp deletion of strain S. epidermidis 8377 com-
prised the ORF of the 19-aa peptide as well as the region
immediately downstream, which included the IR4 and IR5
sequences. This deletion, which has also been reported by
others [14], renders IR6 always accessible to ribosomes,
independently of the presence or absence of inducer.
The erm(A) regulatory region of S. epidermidis 6906
showed complete identity with that of Tn554. Contrary to
previously described [9,17,25], point mutations that could
have accounted for constitutive expression of erm(A) were
not detected. This strain also harbored erm(B) and erm(C)
determinants. PCR amplification and sequence of the erm(C)
regulatory region showed complete identity with that of the
sequence of plasmid pE5 (data not shown). Thus, constitutive
expression of the methylase could be due to erm(B), as the
latter is located on Tn551 in staphylococci and expressed
constitutively [2]. By contrast, in streptococci and certain
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other bacteria, erm(B) is inducible by the entire range of
MLSB antibiotics, and its regulatory region specifies a 155-bp
leader sequence encoding a 36-aa peptide and containing 14
IRs that can potentially form a large number of secondary
structures [3,9]. Like the deletions, tandem duplications, and
point mutations reported in the regulatory regions of erm(A)
and erm(C) [5,8,9,14,25,26], similar alterations may be pres-
ent in the erm(B) regulatory region of this strain that account
for the constitutive phenotype. Furthermore, the erm(C) gene
of this strain was transferred by filter-mating experiments.
The transconjugant obtained presented an inducible pheno-
type, which supports our hypothesis that constitutive expres-
sion is due to erm(B) (data not shown). Nevertheless, further
sequence analysis of the erm(B) regulatory region is currently
being done to verify this hypothesis.
The remaining four strains also showed a PCR product
whose size was indistinguishable from that of the control
strain. In addition, all of them harbored erm(C), and analysis
of the regulatory region of this gene showed that three strains
contained a 107-bp deletion and the other a 58-bp deletion,
which could explain the constitutive phenotype (data not
shown). These alterations in the attenuator have been des-
cribed in constitutively expressed erm(C) genes of naturally
occurring staphylococcal plasmids, such as pSES24 (58-bp
deletion), pNE131, and pSES4a (107-bp deletion) [5,8,26],
and our strains showed complete identity with them.
However, as we did not sequence the translational attenuator
of the erm(A) gene of these strains, there could be other alter-
ations in this region, such as point mutations, or the 10-bp
deletion described in this work (detected only after sequenc-
ing), or other deletions of small size [17], which cannot be
detected without sequencing. Further studies will seek to
determine whether such alterations are present in the erm(A)
regulatory region of these four strains.
To the best of our knowledge, this is the first description
of a 10-bp deletion in the translational attenuator of erm(A)
from a naturally occurring S. epidermidis strain of human ori-
gin. It is the smallest of the deletions reported thus far in this
region and it confers constitutive resistance. Different muta-
tions in the regulatory regions of erm(A) and erm(C) occur-









Fig. 1. Comparison of the regulatory region and the 5′ end of the constitutively expressed erm(A) gene of Staphylococcus epidermidis
6926 with the corresponding region of Tn554 (database accession No. X03216). Shine-Dalgarno sequences SD1 of the 15-aa peptide,
SD2 of the 19-aa peptide, and SD3 of the erm(A) gene are underlined. Inverted repeat sequences (IR1 to IR6) are in bold. Start codons
of the ORFs of the 15-aa peptide, the 19-aa peptide, and the erm(A) gene are double underlined.
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ring in vivo and in vitro after selection in the presence of non-
inducer antibiotics have been reported. Non-inducing MLSB
antibiotics are still widely used in human and in veterinary
medicine. The development of constitutively resistant strains
will strongly reduce the efficacy of these drugs in the control
of pathogenic staphylococci. Thus, the spectrum of resistance
changes from limited resistance to 14- and 15-membered
macrolides to extended resistance to 14-, 15-, and 16-mem-
bered macrolides as well as lincosamides and type B strep-
togramins. Consequently, the use of MLSB antibiotics is not
recommended for the control of staphylococci with an
inducible phenotype [4,7–9,14–17,25,26]. Note also that
alterations in the regulatory region of erm(A) are not only
confined to staphylococci; rather, a 44-bp duplication, a 68-
bp deletion, point mutations and a single base insertion have
also been described in this region in several Streptococcus
pyogenes clinical isolates displaying constitutive MLSB
resistance [1]. Thus, our results confirm that deletions in the
erm(A) regulatory region not only are obtained in the labora-
tory but they also occur in nature, which suggests selective
pressure resulting from the use of MLSB antibiotics.
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